Open Nav

Infectious Disease: Resistance is Futile-SuperDrugs for SuperBugs

Wednesday, October 26th, 1:30pm-2:25pm, Twin Peaks N/S

While new superbugs are on the rise, new superdrugs to combat these remain few and far between.  The incidence of both gram negative and gram positive antibiotic drug resistance continues to increase, and innovative drugs with novel mechanisms of action are sorely needed in the antibiotic pipeline. With large pharma increasingly exiting the antibacterial drug discovery market, the space is ripe for small biotech to fill the void. Hear the companies riding the next wave of antibiotic drug discovery discuss the opportunities and challenges of this ever-evolving field.


  • Susan Schaeffer, Senior Editor, BioCentury Publications 


  • Brian R. Dixon, PhD, President & CEO, BioRelix, Inc.
  • Mark Leuchtenberger, President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc.
  • David P. Perry, Chief Executive Officer,  Anacor Pharmaceuticals, Inc.
  • Jeffrey Stein, PhD, President & CEO, Trius Therapeutics, Inc.

Who's Who



Brian R. Dixon, PhD - Prior to joining BioRelix in October 2007, Dr. Dixon was a Vice President with Bayer HealthCare in West Haven Connecticut. In that position he led a multi-disciplinary organization of up to 130 employees that delivered state-of-the-art expertise in oncology biomarker discovery, new lead discovery, research drug formulation, pharmacokinetics and drug metabolism to Bayer’s global R&D business. In addition he held leadership roles in R&D licensing initiatives, strategic alliances and cross divisional collaborations in translational medicine. From 1998 – 2001 Brian directed Bayer drug discovery efforts in both the Osteoporosis and Oncology therapeutic areas, where his research groups advanced a number of drug candidates into pre-clinical development. Brian was an undergraduate at the University of Michigan, received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and completed post-doctoral training at Harvard University.


Mark Leuchtenberger - Mr. Leuchtenberger joined Rib-X in March 2010, as the Chief Executive Officer, bringing significant expertise in commercial operations, business development and preparing biopharma companies for product approval and commercialization. His experience includes serving as President and Chief Executive Officer of Targanta Therapeutics Corporation where he led the Company's successful IPO and acquisition, President and Chief Executive Officer of Therion Biologics Corporation, a privately held cancer vaccine company, where he supervised the Company's lead product through development and commercial manufacturing build-up and raised over $120 million in private financing. He was also a senior officer at Biogen, where he led Avonex development and launch in the U.S. and subsequently ran North American and international commercial operations. Mr. Leuchtenberger currently serves on the Executive Committee of the MassBio Board of Directors and as a trustee for Beth Israel Deaconess Medical Center. He is a co-founder of Albor Biologics and Alvos Therapeutics. Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University. 


David P. Perry - Mr. Perry has served as Anacor's President and Chief Executive Officer since March 2002 and has been a member of the board of directors since April 2002. In 1997, Mr. Perry founded Chemdex Corporation, which was acquired by NexPrise, Inc., a business-to-business marketplace company that focused on the life-sciences industry, and until November 2001 served as its Chief Executive Officer. In 1995, Mr. Perry co-founded Virogen, a biotech company based in Boston. Mr. Perry has a B.S. from the University of Tulsa and an M.B.A. from Harvard Business School. 


Susan Schaeffer - Susan serves as Managing Editor of BioCentury, the Bernstein Report on BioBusiness and the BioCentury Extra daily newspaper. She joined BioCentury in 2003 after 10 years as a writer and editor in the consumer packaged goods sector, most recently at international strategy consultant Kurt Salmon Associates.


Jeffrey Stein, PhD - Dr. Stein has served as our president and chief executive officer since February 2007 and on our board of directors since 2005. From 2005 through 2007, Dr. Stein was a Kauffman Fellow with the venture capital firm Sofinnova Ventures. He has also served as a Venture Partner with Sofinnova Ventures from 2007 until 2010 and as Director of Venture Development for the University of California, San Diego from 2005 to 2006. From 1999 to 2005, Dr. Stein served as executive vice president, chief scientific officer and a member of the board of directors of Quorex Pharmaceuticals, an anti-infectives company he founded in 1999, which was acquired by Pfizer in 2005. From 1995 to 1999, Dr. Stein was a scientist with Diversa Corporation where he most recently served as principal scientist and head of the anti-infectives discovery team. From 1993 to 1995, Dr. Stein served as Principal Scientist with the Agouron Institute, a private research institution, where he conducted research in bacterial genetics. From 1991 to 1993, he was an Alexander Hollaendar Distinguished Postdoctoral Fellow with the California Institute of Technology. Dr. Stein holds a Ph.D. in biochemistry and microbiology from the University of California, at San Diego.